EX-10.13



 Exhibit 10.13 

EMPLOYMENT AGREEMENT 

This EMPLOYMENT AGREEMENT (the “Agreement”) is
made and entered into effective as of November 7, 2017 (the “Effective Date”), by and between BIONANO GENOMICS, INC. (the “Company”) and
WARREN ROBINSON (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a
“Party”. 
 RECITALS 

The Company desires assurance of the association and services of Executive in order to retain Executive’s experience,
skills, abilities, background and knowledge, and is willing to continue to the engagement of Executive’s services on the terms and conditions set forth in this Agreement. 

Executive desires to be in the employ of the Company, and is willing to accept employment on the terms and conditions set
forth in this Agreement. 
 AGREEMENT 

In consideration of the foregoing Recitals and mutual promises and covenants contained herein, and for other good and valuable
consideration, the Parties, intending to be legally bound, agree as follows: 
  

	 	 1.
	 EMPLOYMENT. 



1.1 Title. Executive’s position shall be Chief Commercial Officer of the Company, subject to the terms and
conditions set forth in this Agreement. 
 1.2 Term. The term of this Agreement shall begin on the Effective
Date, and shall continue until terminated in accordance with Section 4 herein (the “Term”). 

1.3 Duties. Executive shall do and perform all services, acts or things necessary or advisable to manage and
conduct the business of the Company and that are normally associated with the position of Chief Commercial Officer, and such other duties as may from time to time be assigned to Executive. Executive shall report to the Chief Executive Officer of the
Company. 
 1.4 Policies and Procedures. The employment relationship between the Parties shall be governed by
this Agreement and by the policies and practices established by the Company and/or the Company’s Board of Directors (the “Board”), or any designated committee thereof. In the event the terms of this Agreement differ from
or are in conflict with the Company’s policies and practices or the Company’s Employee Handbook, this Agreement shall control, 

1.5 Location. Unless the Parties otherwise agree in writing, during the Term Executive shall perform the
services Executive is required to perform pursuant to this Agreement at the Company’s offices in San Diego, California provided, however, that the Company may 

  
 1. 








 
from time to time require Executive to travel temporarily to other locations in connection with the Company’s business. 

 

	 	 2.
	 LOYAL;
NON-COMPETITION; NON-SOLICITATION. 



2.1 Loyalty. Except as expressly provided herein, during Executive’s employment by the Company, Executive
shall devote Executive’s full business energies, interest, abilities and productive time to the proper and efficient performance of Executive’s duties under this Agreement. 

2.2 Agreement not to participate in Company’s Competitors. During Executive’s employment with the
Company, Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or
in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its Affiliates (as defined below). Ownership by Executive, in professionally managed funds over which the Executive does not
have control or discretion in investment decisions, or as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a national securities
exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute a breach of this Section. For purposes of this
Agreement, “Affiliate” means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls is controlled by or is under common control with such specified entity. 

2.3 Covenant not to Compete. During Executive’s employment with the Company, the Executive shall not engage
in competition with the Company and/or any of its Affiliates, either directly or indirectly, in any manner or capacity, as adviser, principal, agent, affiliate, promoter, partner, officer, director, employee, stockholder, owner, co-owner, consultant, or member of any association or otherwise, in any phase of the business of developing, manufacturing and marketing of products or services that are in the same field of use or which otherwise
compete with the products or services of the Company except with the prior written consent of the Company. 
  

	 	 3.
	 COMPENSATION OF EXECUTIVE.



 3.1 Base Salary. The Company shall pay Executive a base salary at the annualized rate of
$275,392.17 per year (the “Base Salary”), less payroll deductions and all required withholdings, payable in regular bi-weekly payments or otherwise in accordance with Company policy.
Such Base Salary shall be prorated for any partial year of employment on the basis of a 365-day fiscal year. 

3.2 Discretionary Bonus. At the sole discretion of the Company, following each calendar year of employment,
Executive shall be eligible to receive a discretionary cash bonus with a target amount of up to thirty point two percent (30.2%) of Executive’s then-current base salary (the “Bonus”), based on Executive’s
achievement relative to certain performance goals (“Performance Goals”) to be established by the Company. The determination of whether 

  
 2. 








 
Executive has met the Performance Goals for any given year, and if so, the amount of any Bonus that will be paid for such year (if any), shall be determined by the Company in its sole and
absolute discretion, In order to be eligible to earn or receive any Bonus, Executive must remain employed by the Company through and including the end of the year with respect to which such Bonus is earned. 

3.3 Expense Reimbursement. The Company will reimburse Executive for all reasonable business expenses Executive
incurs in conducting his duties hereunder, pursuant to the Company’s usual expense reimbursement policies; provided that Executive supplies the appropriate substantiation for such expenses no later than the end of the calendar month following
the month in which such expenses were incurred by Executive, For the avoidance of doubt, to the extent that any expense reimbursements payable to Executive under Section 3.3 above or this Section 3.4 are taxable income and subject to the
provisions of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively
“Section 409A”): (i) to be eligible to obtain reimbursement for such expenses Executive must supply the appropriate documentation substantiating such expenses no later than the end of the
calendar month following the month in which such expenses were incurred by Executive, (ii) any such reimbursements will be paid by the Company as soon as administratively practicable after submission of such documentation, but in no event later
than December 31 of the year following the year in which the expense was incurred, (iii) the amount of expenses reimbursed i n one year will not affect the amount eligible for reimbursement in any subsequent year, and (iv) the right
to expense reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit, 

3.4 Changes to Compensation. Executive’s compensation will be reviewed annually and may be increased from
time to time in the Company’s sole discretion. 
 3.5 Employment Taxes. All of Executive’s
compensation and payments under this Agreement shall be subject to customary withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company. 

3.6 Benefits. Executive shall, in accordance with Company policy and the terms of the applicable plan documents,
be eligible to participate in benefits under any benefit plan or arrangement which may be in effect from time to time and made available to the Company’s executive or key management employees. 

3.7 Holidays and Vacation. Executive shall be eligible for paid holiday and vacation time in accordance with
Company policy as in effect from time to time and made available to Company’s senior management employees. 
  

  
 3. 









	 	 4.
	 TERMINATION. 



4.1 Termination by the Company. Executive’s employment with the Company is at will and may be terminated by
the Company at any time and for any reason, or for no reason, including, but not limited to, under the following conditions: 

4.1.1 Termination by the Company for Cause. The Company may terminate Executive’s employment under this
Agreement for Cause by delivery of written notice to Executive. Any notice of termination given pursuant to this Section shall effect termination as of the date of the notice, or as of such other date specified in the notice, 

4.1.2 Termination by the Company without Cause. The Company may terminate Executive’s employment under
this Agreement without Cause at any time and for any reason, or for no reason. Such termination shall be effective on the date Executive is so informed by the Company. 

4.2 Termination by Executive. Executive may terminate his employment with the Company at any time and for any
reason, or for no reason, upon thirty (30) days written notice to the Company. 
 4.3 Termination for Death
or Complete Disability. Executive’s employment with the Company shall automatically terminate effective upon the date of Executive’s death or Complete Disability (as defined below). 

4.4 Termination by Mutual Agreement of the Parties. Executive’s employment with the Company may be
terminated at any time upon a mutual agreement in writing of the Parties. Any such termination of employment shall have the consequences specified in such agreement. 

4.5 Compensation upon Termination. 

4.5.1 Death or Complete Disability. If Executive’s employment with the Company is terminated as a result of
Executive’s death or Complete Disability, the Company shall pay to Executive, or to Executive’s heirs, Executive’s base salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect at
the time of termination, less standard deductions and withholdings. The Company shall thereafter have no further obligations to Executive and/or Executive’s heirs under this Agreement, except as otherwise provided by law (and except as provided
otherwise in Executive’s stock option agreements with the Company). 
 4.5.2 With Cause or Without Good
Reason. If Executive’s employment with the Company is terminated at any time either by the Company for Cause or by Executive without Good Reason, the Company shall pay the Accrued Obligations, and the Company shall thereafter have no
further obligations to Executive under this Agreement, except as otherwise provided by law (and except as provided otherwise in Executive’s stock option agreements with the Company). 

4.5.3 Without Cause or for Good Reason. If Executive’s employment with the Company is terminated by the
Company without Cause or by Executive for Good 

  
 4. 








 
Reason, and in either case Executive signs a separation agreement including a comprehensive waiver and release of claims in such form as the Company may require (the
“Release”) on or within the time period set forth therein, but in no event later than 45 days after Executive’s termination date, and allows such Release to become effective in accordance with its terms (such latest
permitted date on which the Release could become effective, the (“Release Deadline”), then Executive will receive the following benefits: 

4.5.3.1 Severance Payment. Cash payments in the form of continuation of Executive’s Base Salary at the
rate in effect at the time of termination for a period of six (6) months following the termination date and, (“Severance Payment”) 

4.5.3.2 Benefits. Provided that Executive is eligible for and timely elects continued group health coverage
under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) following Executive’s termination date, the Company shall pay directly to the insurance provider the premium for COBRA continuation coverage for
the Executive and Executive’s family for a period that will expire upon the earliest of (i) six (6) months following the termination date (the “COBRA Payment Period”), (ii) the effective date that Executive becomes
eligible for new healthcare coverage eligibility available through new employment, or (iii) the date Executive is no longer eligible for COBRA coverage, whichever comes first. 

4.5.4 General Severance Benefit Terms. 

4.5.4.1 The provisions in this Section 4.5.5.1 shall control and supersede anything to the contrary set forth in
this Agreement. For all purposes of this Agreement, references to COBRA premiums shall not include any amounts payable by Executive under a Section 125 health care reimbursement plan under the Code. If at any time the Company determines, in its
sole discretion, that it cannot pay the COBRA premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then regardless of whether
Executive elects continued health coverage under COBRA, and in lieu of providing COBRA premiums, the Company will instead pay Executive on the last day of each remaining month of the COBRA Payment Period a fully taxable cash payment equal to the
CBRA premiums for that month, subject to applicable tax withholdings, which payments shall continue until the earlier of expiration of the COBRA Payment Period of the date when Executive becomes eligible for health insurance coverage in connection
with new employment. If Executive becomes eligible for coverage under another employer’s group health plan, Executive must immediately notify the Company of such event, and all COBRA severance benefit payments and obligations under this
Agreement shall cease effective as of such date of Executive’s eligibility. 
 4.5.4.2 If All severance
payments made under this Agreement will be subject to standard payroll deductions and withholdings and will be made on the Company’s regular payroll cycle, provided, however, that any severance payments otherwise scheduled to be made prior to
the effective date of the Release shall instead accrue and be paid in the first payroll period that follows such effective date. Following provisions of any severance benefits to which the Executive may be entitled under Section 4.5.3, the
Company shall thereafter have no further obligations to Executive under this Agreement, except as otherwise 

  
 5. 








 
provided by law (and except as provided otherwise in Executive’s stock option agreements with the Company). 

4.6 Additional Definitions. For the purposes of this Agreement, the following terms shall have the following
meanings: 
 4.6.1 “Complete Disability” shall mean the inability of executive to perform
Executive’s duties under this Agreement, whether with or without reasonable accommodation, because Executive has become permanently disabled within the meaning of any policy of disability income insurance covering employees of the Company then
in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when Executive becomes disabled, the term “Complete Disability” shall mean the inability of Executive
to perform Executive’s duties under this Agreement, whether with or without reasonable accommodation, by reason of any incapacity, physical or mental, which the Company, based upon medical advice or an opinion provided by a licensed physician
acceptable to the Company, determines to have incapacitated Executive from satisfactorily performing all of Executive’s usual services for the Company, with or without reasonable accommodation, for a period of at least on hundred twenty
(120) days during any twelve (12) month period (whether or not consecutive). Based upon such medical advice or opinion, the determination of the Company shall be final and binding and the date such determination is made shall be the date
of such Complete Disability for purposes of this Agreement. 
 4.6.2 “Cause” shall mean the
occurrence of any of the following: (i) Executive’s conviction of any felony or any crime involving fraud or dishonesty that has a material adverse effect on the Company; (ii) Executive’s active participation (whether by
affirmative act or material omission) in a fraud, act of dishonesty or other act of misconduct against the Company and/or its affiliates; (iii) conduct by Executive which, based upon a good faith and reasonable factual investigation by the
Company, demonstrates Executive’s gross unfitness to serve; (iv) Executive’s material violation of any statutory or fiduciary duty, or duty of loyalty, owed to the Company; (v) Executive’s breach of any material term of any
material contract between such Executive and the Company and the failure to cure such breach within 30 days of written notice; and (vi) Executive’s repeated violation of any material Company policy. Executive’s Complete Disability
shall not constitute Cause as set forth herein. The determination that a termination is for Cause shall be by the Company in its sole and exclusive judgement and discretion. 

4.6.3 Good Reason. “Good Reason” for Executive to terminate Executive’s employment
hereunder shall mean the occurrence of any of the following events without Executive’s consent; provided however, that any resignation by Executive due to any of the following conditions shall only be deemed for Good Reason if
(i) Executive gives the Company written notice of the intent to terminate for Good Reason within 90 days following the first occurrence of the condition(s) that Executive believes constitutes Good Reason, which notice shall describe such
condition(s); (ii) the Company fails to remedy, if remediable, such condition(s) within 30 days following receipt of the written notice (the “Cure Period”) of such condition(s) from Executive; and (iii) Executive
actually resigns his employment within the first 15 days after expiration of the Cure Period: 

  
 6. 








 4.6.3.1 a material breach of this Agreement by the Company; 

4.6.3.2 a material reduction (but not less than 10%) by the Company of Executive’s Base Salary as initially set
forth herein or as the same may be increased from time to time, unless such reduction is part of a reduction program equally applicable to other executive employees of the Company; 

4.6.3.3 a material reduction in Executive’s authority, duties or responsibilities; or 

4.6.3.4 the Company relocates the facility that is Executive’s principal place of business with the Company to a
location that requires an increase in Executive’s one-way driving distance by more than 50 miles. 

4.7 Survival of Certain Provisions. Sections 2, 3.5 and 4 through 19 of this Agreement shall survive the
termination of this Agreement. 
 4.8 Parachute Payments. Except as otherwise provided in an agreement between
Executive and the Company, if any payment or benefit Executive would receive from the Company or otherwise in connection with a Change in Control (“Payment”) would (i) constitute a “parachute payment” within the meaning of
Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount (as defined herein). The
“Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (y) the largest portion, up to and including the total, of the Payment,
whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute
payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit to Executive. 

The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the
effective date of the event described in Section 280G(b)(2)(A)(i) of the Code shall perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the
individual, entity or group effecting such event, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder, The Company shall bear all expenses with respect to the
determinations by such independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed
supporting documentation, to the Company and Executive within thirty (30) calendar days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as
reasonably requested by the Company or Executive. Any good faith determinations of the 

  
 7. 








 
independent registered public accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive. 

4.9 Application of Internal Revenue Code Section 409A. 

All benefits under this Agreement are intended to qualify for an exemption from application of Section 409A of the Code
and the regulations and other guidance thereunder and any state law of similar effect (“Section 409A”) or to comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and
any ambiguities herein shall be interpreted accordingly. 
 Notwithstanding anything to the contrary set forth herein, any
severance benefits that constitute “deferred compensation” within the meaning of Section 409A shall not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a
“separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h)) (“Separation From Service”), unless the Company reasonably determines that such amounts
may be provided to Executive without causing Executive to incur the additional 20% tax under Section 409A. 
 It is
intended that each installment of the severance benefit payments provided for in this Agreement is a separate “payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the
avoidance of doubt, it is intended that payments of the severance benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if the Company (or, if applicable, the successor entity thereto) determines
that the severance benefits constitute “deferred compensation” under Section 409A and Executive is, on the termination of service, a “specified employee” of the Company or any successor entity thereto, as such term is
defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the severance benefit payments shall be delayed until
the earlier to occur of: (i) the date that is six months and one day after Executive’s Separation From Service, or (ii) the date of Executive’s death. None of the severance benefits will be paid or otherwise delivered prior to
the effective date of the Release. If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the calendar year in which
Executive’s Separation From Service occurs, the Release will not be deemed effective any earlier than the Release Deadline. Except to the minimum extent that payments must be delayed because Executive is a “specified employee” or
until the effectiveness of the Release, all amounts will be paid as soon as practicable in accordance with the Company’s normal payroll practices. 

The severance benefits are intended to qualify for an exemption from application of Section 409A or comply with its requirements to the
extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly. 
  

  
 8. 









	 	 5.
	 CONFIDENTIAL AND PROPRIETARY
INFORMATION; NONSOLICITATION. 


 5.1 As a condition
of employment, Executive agrees to execute and abide by the Company’s Confidential Information and Inventions Assignment Agreement attached hereto as EXHIBIT A. 

5.2 While employed by the Company and for one year thereafter, Executive agrees that in order to protect the
Company’s trade secrets and confidential and proprietary information from unauthorized use, Executive will not, either directly or through others, solicit or attempt to solicit any employee, consultant or independent contractor of the Company
to terminate his or her relationship with the Company in order to become an employee, consultant or independent contractor to or for any other person or business entity. 
  

	 	 6.
	 ASSIGNMENT AND BINDING
EFFECT. 


 This Agreement shall be binding upon and inure to the benefit
of Executive and Executive’s heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of Executive’s duties under this Agreement, neither this Agreement nor
any rights or obligations under this Agreement shall be assignable by Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives. 

 

	 	 7.
	 NOTICES. 



All notices or demands of any kind required or permitted to be given by the Company or Executive under this Agreement shall be
given in writing and shall be personally delivered (and receipted for) or faxed during normal business hours or mailed by certified mail return receipt requested, postage prepaid, address as follows, 

 

							
		 	 If to the Company:
  

Attn: Chief Executive Officer

Bionano Genomics, Inc.
 9640 Towne
Centre Drive, Suite 100
 San Diego, CA 92121
	  	 If to Executive:
  

Warren Robinson
 6210 Silverdawn
Court
 Kingwood, TX 77345
  
	  	

 Any such written notice shall be deemed given on the earlier of the date on which such notice
is personally delivered or three (3) days after its deposit in the United States mail as specified above. Either Party may change its address for notices by giving notice to the other Party in the manner specified in this Section. 

 

	 	 8.
	 CHOICE OF LAW.



 This Agreement shall be construed and interpreted in accordance with the internal laws of the State of
California without regard to its conflict of laws principles. 
  

	 	 9.
	 INTEGRATION. 



This Agreement, including Exhibit A, contains the complete, final and exclusive agreement of the Parties relating to the terms
and conditions of Executive’s employment and the 

  
 9. 








 
termination of Executive’s employment, and supersedes all prior and/or contemporaneous oral and written employment agreements or arrangements between the Parties. 

 

	 	 10.
	 AMENDMENT. 



This Agreement cannot be amended or modified except by a written agreement signed by Executive and the Company. 

 

	 	 11.
	 WAIVER. 



No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent
of the Party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach.

  

	 	 12.
	 SEVERABILITY. 



The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this
Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or
provision which most accurately represents the Parties’ intention with respect to the invalid or unenforceable term or provision. 
  

	 	 13.
	 INTERPRETATION; CONSTRUCTION.



 The headings set forth in this Agreement are for convenience of reference only and shall not be used in
interpreting this Agreement. This Agreement has been drafted by legal counsel representing the Company, but Executive has been encouraged to consult with, and have consulted with, Executive’s own independent counsel and tax advisors with
respect to the terms of this Agreement. The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any ambiguities are
to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. 
  

	 	 14.
	 REPRESENTATIONS AND WARRANTIES.



 Executive represents and warrants that Executive is not restricted or prohibited, contractually or
otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that Executive’s execution and performance of this Agreement will not violate or breach any other agreements between Executive and any
other person or entity. 
  

  
 10. 









	 	 15.
	 COUNTERPARTS; FACSIMILE. 



This Agreement may be executed in two counterparts, each of which shall be deemed an original, all of which together shall
contribute one and the same instrument. Facsimile signatures shall be treated the same as original signatures. 
  

	 	 16.
	 DISPUTE RESOLUTION. 



To ensure the timely and economical resolution of disputes that may arise in connection with Executive’s employment with
the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Executive’s
employment, or the termination of Executive’s employment, including but not limited to statutory claims, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in
Sacramento, California, conducted by JAMS, Inc. (“JAMS”) under the then applicable JAMS rules (which can be found at the following web address: http://www.jamsadr.com/rulesclauses). By agreeing to this arbitration procedure,
both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The Company acknowledges that Executive will have the right to be represented by legal counsel at any
arbitration proceeding. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration
decision, to include the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law.
The Company shall pay all JAMS’ arbitration fees in excess of the amount of court fees that would be required of Executive if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the
Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any
competent jurisdiction, 
  

	 	 17.
	 TRADE SECRETS OF
OTHERS. 


 It is the understanding of both the Company and Executive that
Executive shall not divulge to the Company and/or its subsidiaries any confidential information or trade secrets belonging to others, including Executive’s former employers, nor shall the Company and/or its Affiliates seek to elicit from
Executive any such information. Consistent with the foregoing, Executive shall not provide to the Company and/or its Affiliates, and the Company and/or its Affiliates shall not request, any documents or copies of documents containing such
information. 
  

	 	 18.
	 ADVERTISING WAIVER. 



Executive agrees to permit the Company and/or its affiliates, subsidiaries, or joint ventures currently existing or which shall
be established during Executive’s employment by the Company (collectively, “Affiliates”), and persons or other organizations authorized by the Company and/or its Affiliates, to use, publish and distribute advertising or
sales promotional literature concerning the products and/or services of the Company and/or its Affiliates, or the machinery and equipment used in the provision thereof, in which Executive’s name and/or


  
 11. 








 
pictures of Executive taken in the course of Executive’s provision of services to the Company and/or its Affiliates, appear. Executive hereby waives and releases any claim or right Executive
may otherwise have arising out of such use, publication or distribution. The Company agrees that, following termination of Executive’s employment, it will not create any new such literature containing Executive’s name and/or pictures
without Executive’s prior written consent. 
  

	 	 19.
	 INDEMNIFICATION. 



Subject to applicable law, Executive will be provided indemnification to the maximum extent permitted by the Company’s
Bylaws and Articles of Incorporation, including coverage, if applicable, under any directors and officers insurance policies, with such indemnification determined by the Board or any of its committees in good faith based on principles consistently
applied (subject to such limited exceptions as the Board may approve in cases of hardship) and on terms no less favorable than provided to any other Company executive officer or director. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 12. 








 IN WITNESS WHEREOF, the
Parties have executed this Agreement as of the date first above written. 
 BIONANO GENOMICS,
INC 
  

			
	 By:
	 	 /s/ R. Erik Holmlin

		 	 R. Erik Holmlin, President and CEO



			
		
	 Date:
	 	 Nov 7, 2017

	
	 EXECUTIVE

	
	 /s/ Warren
Robinson



			
	 Warren Robinson



			
		
	 Date:
	 	 11/07/2017









 EXHIBIT A 

CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT
AGREEMENT